Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Synairgen’s SNG001 will prevent cell damage in fight against coronavirus pandemic

Synairgen has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled interferon-beta-1a) in coronavirus (COVID-19) patients. SNG001 will prevent cell damage in a similar fashion to that of multiple sclerosis (MS) patients, says GlobalData, a leading data and analytics company. Synairgen […]
Read more

APAC axial spondyloarthritis market to grow moderately over next decade due to uptake of expensive biologic therapies, says GlobalData

The axial spondyloarthritis (axSpA) market across the five growth markets (5GM*) in the Asia-Pacific (APAC) region will experience moderate growth over the next 10 years, which can be attributed to the increased uptake of expensive biologic therapies in India and China along with the imminent arrival of new interleukin-17 (IL-17) inhibitors and Janus kinase (JAK) […]
Read more

COVID-19 cases in US could total more than 228,000 by end of March

There has been an exponential increase of coronavirus (COVID-19) cases in the US since the beginning of March, from less than 70 to more than 4,000. In just two more weeks, there could be over 228,000 confirmed cases, says GlobalData, a leading data and analytics company. Kasey Fu, Director of Epidemiology at GlobalData, comments: “Depending […]
Read more

Tessa Therapeutics TT11 will replace stem cell transplants as standard of care in Hodgkin’s lymphoma

Tessa Therapeutics’ TT11 has become the first CAR-T therapy to receive the Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation and is set to become the leading cell-based therapy in Hodgkin’s lymphoma (HL), displacing the outdated stem cell transplants as the standard of care by 2024, says GlobalData, a leading data and analytics company. Miguel Ferreira, MSc, Oncology and Hematology Analyst at GlobalData, comments: “TT11, being the first CAR-T therapy to emerge from […]
Read more

Angina landscape shifting towards increased recognition of microvascular angina in clinical practice

Microvascular angina (MVA) is being increasingly recognized in clinical practice, says GlobalData, a leading data and analytics company. According to key opinion leaders (KOLs) interviewed by GlobalData, patients with exertional angina and symptoms strongly suggestive of coronary artery disease (CAD) were previously often disregarded since the diagnosis of chronic stable angina was highly related to […]
Read more

Supply disruption scares and price hikes wakeup call for India to reduce dependence on China for APIs, says GlobalData

The impact of the coronavirus (Covid-19) outbreak on industries ranging from technology to automotive has been the subject of intense analysis in the recent months. This has exposed dependence of India on China for its active pharmaceutical ingredient (API) requirements. For India’s pharma industry, which is staring at a probable supply chain disruption of APIs, […]
Read more

Lipaglyn gives Zydus Cadila first mover advantage in lucrative NASH market, says GlobalData

Following the recent news that The Drug Controller General of India (DCGI) has approved Zydus Cadila’s new drug application (NDA) for Lipaglyn (saroglitazar) for treatment of Non-Cirrhotic, Non-Alcoholic Steatohepatitis (NASH) in India; Nag Madhavi, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “Lipaglyn, which is a novel first in class […]
Read more

MD1003 Phase III trial failure for multiple sclerosis treatment not wholly unexpected

Following the news that MedDay Pharmaceutical’s MD1003 for the treatment of non-active progressive forms of multiple sclerosis (MS) failed in a Phase III clinical trial; Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Despite MD1003 demonstrating efficacy at reversing disease progression in a small percentage of […]
Read more

Systemic lupus erythematosus and lupus nephritis market to be worth $1.6bn by 2028 driven by launch of six pipeline therapies, says GlobalData

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market is expected to grow from $935.9M in 2018 to $1.6bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 5.6%, according to GlobalData, a leading data and analytics company. The company’s latest report, Systemic Lupus Erythematosus and Lupus Nephritis: […]
Read more

Global bladder cancer market set to reach $4.0bn by 2028

The bladder cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 18.5%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Bladder cancer: Opportunity Analysis and Forecast to 2028’, states that the main driver of growth will be the approval and launch of pipeline therapies in multiple treatment […]
Read more

As coronavirus spreads, mitigation may be better strategy than quarantine

The statement from the World Health Organization (WHO) that we are in “uncharted territory” on the coronaries outbreak comes as no surprise as Covid-19 infections are spreading beyond China at an alarming pace, with several clusters of outbreaks being reported in Europe, the Middle East and Asia. Governments should start to consider focusing on mitigation […]
Read more

Cipla’s digital initiatives in respiratory space can be an exemplar for other leading Indian pharma companies, says GlobalData

Digital marketing in pharma is gaining increasing importance in recent times and Indian multinational pharmaceutical company Cipla Limited can be termed as a pioneer in this space from the Indian market perspective as it has successfully used a digital strategy to promote disease awareness and grow leadership position in asthma, says GlobalData, a leading data […]
Read more

Clinical worthiness of microbiome-based approaches for melanoma unclear, says GlobalData

Gut bacteria research is seeing a resurgence in drug development, including beyond gastrointestinal disorders, with pharmaceutical companies diving into microbiome-focused cancer therapeutic candidates. Experts, however, are taking a cautious stance when it comes to treating melanoma, according to reporting by Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and […]
Read more

Innovations in CAR-T therapies across APAC will make global market more competitive, says GlobalData

There are currently 445 chimeric antigen receptor (CAR-T cell) therapies under development by companies headquartered across the Asia-Pacific (APAC) region. With research in progress and increased understanding of cancer biology, the new therapies are expected to make the global market more competitive and cost effective, says GlobalData, a leading data and analytics company. GlobalData’s research […]
Read more
1 … 99 100 101 102 103 … 108